NASDAQ:CTRV - ContraVir Pharmaceuticals News Headlines

$8.89
-1.22 (-12.07 %)
(As of 06/17/2019 03:08 AM ET)
Today's Range
$8.62
Now: $8.89
$10.66
50-Day Range
$0.1070
MA: $1.89
$9.07
52-Week Range
$4.80
Now: $8.89
$117.60
Volume468,294 shs
Average Volume917,821 shs
Market Capitalization$6.49 million
P/E RatioN/A
Dividend YieldN/A
Beta1.6

Headlines

ContraVir Pharmaceuticals (NASDAQ CTRV) News Headlines

Source:
DateHeadline
ContraVir Says SEC Filing Made In Error, Stock Moves DownContraVir Says SEC Filing Made In Error, Stock Moves Down
www.benzinga.com - June 14 at 8:11 PM
ContraVir up 21% on positive CRV431 data in hepatitis BContraVir up 21% on positive CRV431 data in hepatitis B
seekingalpha.com - June 12 at 5:36 PM
Why Low-Float, Thinly Traded ContraVir Pharmas Rally Is ContinuingWhy Low-Float, Thinly Traded ContraVir Pharma's Rally Is Continuing
finance.yahoo.com - June 11 at 7:13 PM
ContraVir Pharmaceuticals Announces Publication of CRV431 Data from Experimental Model of Hepatitis BContraVir Pharmaceuticals Announces Publication of CRV431 Data from Experimental Model of Hepatitis B
finance.yahoo.com - June 11 at 8:52 AM
Why ContraVir Pharmaceuticals (CTRV) Is Skyrocketing TodayWhy ContraVir Pharmaceuticals (CTRV) Is Skyrocketing Today
investorplace.com - June 7 at 2:56 PM
CIEN, CTRV among premarket gainersCIEN, CTRV among premarket gainers
seekingalpha.com - June 6 at 7:01 PM
ContraVir Pharmaceuticals Sets the Stage for CRV431 Development in NASH with Positive Results from Second Model of Liver FibrosisContraVir Pharmaceuticals Sets the Stage for CRV431 Development in NASH with Positive Results from Second Model of Liver Fibrosis
finance.yahoo.com - June 6 at 8:26 AM
Zacks: ContraVir Pharmaceuticals Inc (CTRV) Receives Average Recommendation of "Hold" from AnalystsZacks: ContraVir Pharmaceuticals Inc (CTRV) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - June 3 at 10:19 AM
ContraVir down 8% premarket on 1:70 reverse stock splitContraVir down 8% premarket on 1:70 reverse stock split
seekingalpha.com - May 31 at 6:49 PM
Head-To-Head Analysis: ContraVir Pharmaceuticals (CTRV) & ImmunoGen (IMGN)Head-To-Head Analysis: ContraVir Pharmaceuticals (CTRV) & ImmunoGen (IMGN)
www.americanbankingnews.com - May 31 at 6:16 PM
ContraVir Pharmaceuticals Receives Positive Nasdaq Listing DecisionContraVir Pharmaceuticals Receives Positive Nasdaq Listing Decision
finance.yahoo.com - May 6 at 8:28 AM
ContraVir Pharmaceuticals to Present at the 2019 ThinkEquity ConferenceContraVir Pharmaceuticals to Present at the 2019 ThinkEquity Conference
finance.yahoo.com - April 29 at 6:39 PM
ContraVir prices equity offering; shares down 51% premarketContraVir prices equity offering; shares down 51% premarket
seekingalpha.com - April 25 at 7:11 PM
ContraVir Pharmaceuticals Inc.ContraVir Pharmaceuticals Inc.
www.barrons.com - April 25 at 7:11 PM
ContraVir Pharmaceuticals, Inc. Announces Pricing of $2.14 Million Public OfferingContraVir Pharmaceuticals, Inc. Announces Pricing of $2.14 Million Public Offering
finance.yahoo.com - April 25 at 7:11 PM
ContraVir And CRV431 In NASH: An UpdateContraVir And CRV431 In NASH: An Update
seekingalpha.com - April 25 at 8:24 AM
ContraVir Pharmaceuticals to Present CRV431 Phase 1 Data at the International Liver Congress™ContraVir Pharmaceuticals to Present CRV431 Phase 1 Data at the International Liver Congress™
finance.yahoo.com - April 11 at 9:25 AM
ContraVir Pharmaceuticals Announces Panel Participation at 31st Annual ROTH Conference - GlobeNewswireContraVir Pharmaceuticals Announces Panel Participation at 31st Annual ROTH Conference - GlobeNewswire
globenewswire.com - March 5 at 8:50 AM
ContraVir Pharmaceuticals Announces Panel Participation at 31st Annual ROTH ConferenceContraVir Pharmaceuticals Announces Panel Participation at 31st Annual ROTH Conference
finance.yahoo.com - March 4 at 7:51 PM
ContraVir files for equity offering - Seeking AlphaContraVir files for equity offering - Seeking Alpha
seekingalpha.com - January 30 at 6:57 PM
ContraVir Pharmaceuticals Announces Adjournment of Annual Meeting of StockholdersContraVir Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders
finance.yahoo.com - January 16 at 8:25 AM
Investors Should Vote No On ContraVirs Stock Incentive ProposalInvestors Should Vote 'No' On ContraVir's Stock Incentive Proposal
seekingalpha.com - December 3 at 5:11 PM
ContraVir Pharmaceuticals to Present CRV431 Preclinical Data at the Anti-Fibrotic Drug Development SummitContraVir Pharmaceuticals to Present CRV431 Preclinical Data at the Anti-Fibrotic Drug Development Summit
finance.yahoo.com - November 27 at 5:13 PM
ContraVir Pharmaceuticals to Present Two Posters at The Liver Meeting® 2018, Hosted by the American Association ...ContraVir Pharmaceuticals to Present Two Posters at The Liver Meeting® 2018, Hosted by the American Association ...
globenewswire.com - November 6 at 8:23 AM
ContraVir Pharmaceuticals to Present Two Posters at The Liver Meeting® 2018, Hosted by the American Association for the Study of Liver DiseasesContraVir Pharmaceuticals to Present Two Posters at The Liver Meeting® 2018, Hosted by the American Association for the Study of Liver Diseases
finance.yahoo.com - November 6 at 8:23 AM
ContraVir Pharmaceuticals Completes Final Cohort Dosing in CRV431 Drug-Drug Interaction StudyContraVir Pharmaceuticals Completes Final Cohort Dosing in CRV431 Drug-Drug Interaction Study
finance.yahoo.com - October 30 at 8:27 AM
Leading BioSciences Announces Appointments of James R. Neal and James Sapirstein to Board of DirectorsLeading BioSciences Announces Appointments of James R. Neal and James Sapirstein to Board of Directors
finance.yahoo.com - October 30 at 8:27 AM
Matinas BioPharma Appoints Global Pharmaceutical Drug Development Industry Leader Theresa Matkovits, Ph.D ...Matinas BioPharma Appoints Global Pharmaceutical Drug Development Industry Leader Theresa Matkovits, Ph.D ...
www.nasdaq.com - October 15 at 8:26 AM
A Letter To The New CEO Of ContraVir PharmaceuticalsA Letter To The New CEO Of ContraVir Pharmaceuticals
seekingalpha.com - October 5 at 8:24 AM
Robert Foster Appointed Acting Chief Executive Officer of ContraVir Pharmaceuticals, Inc.Robert Foster Appointed Acting Chief Executive Officer of ContraVir Pharmaceuticals, Inc.
finance.yahoo.com - October 3 at 8:25 AM
ContraVir: A Speculative Contrarian Bet With Lots Of Upside Potential Part IIContraVir: A Speculative Contrarian Bet With Lots Of Upside Potential Part II
seekingalpha.com - October 2 at 4:49 PM
ContraVir completes Phase 1 study supporting CRV431; shares up 14% premarketContraVir completes Phase 1 study supporting CRV431; shares up 14% premarket
seekingalpha.com - September 18 at 4:56 PM
ContraVir Pharmaceuticals Announces Completion of Phase 1 with CRV431ContraVir Pharmaceuticals Announces Completion of Phase 1 with CRV431
finance.yahoo.com - September 18 at 4:56 PM
ContraVir Pharmaceuticals Announces Participation at the 20th Annual Global Investment Conference in New York City September 4-6, 2018ContraVir Pharmaceuticals Announces Participation at the 20th Annual Global Investment Conference in New York City September 4-6, 2018
finance.yahoo.com - August 30 at 5:13 PM
ContraVir Pharma (CTRV) Completes Data Analysis of Second Cohort in Part 1 of Phase 1/2a Study of CRV431ContraVir Pharma (CTRV) Completes Data Analysis of Second Cohort in Part 1 of Phase 1/2a Study of CRV431
www.streetinsider.com - August 9 at 8:38 AM
ContraVir Pharmaceuticals Completes Data Analysis of Second Cohort in Part 1 of the Phase 1/2a Study of CRV431ContraVir Pharmaceuticals Completes Data Analysis of Second Cohort in Part 1 of the Phase 1/2a Study of CRV431
finance.yahoo.com - August 7 at 5:19 PM
ContraVir Pharmaceuticals Provides an Update to Corporate ObjectivesContraVir Pharmaceuticals Provides an Update to Corporate Objectives
finance.yahoo.com - August 6 at 5:29 PM
ContraVir Rises on Early Hepatitis B Drug StudyContraVir Rises on Early Hepatitis B Drug Study
www.baystreet.ca - July 23 at 4:34 PM
ContraVir Pharma (CTRV) Reports Progress in Phase 1/2A Trial of CRV431ContraVir Pharma (CTRV) Reports Progress in Phase 1/2A Trial of CRV431
www.streetinsider.com - July 23 at 8:19 AM
ContraVir Pharmaceuticals Reports Progress in Phase 1/2A Trial of CRV431ContraVir Pharmaceuticals Reports Progress in Phase 1/2A Trial of CRV431
finance.yahoo.com - July 23 at 8:19 AM
ContraVir Pharmaceuticals to Present at Virtual Investor ConferenceContraVir Pharmaceuticals to Present at Virtual Investor Conference
finance.yahoo.com - July 5 at 5:01 PM
ContraVir Pharmaceuticals Announces $10.8 Million in Expected Gross Proceeds from Recently Expired Rights OfferingContraVir Pharmaceuticals Announces $10.8 Million in Expected Gross Proceeds from Recently Expired Rights Offering
finance.yahoo.com - June 30 at 8:50 AM
ContraVir Pharmaceuticals Initiates Dosing of CRV431 in First In-Human TrialContraVir Pharmaceuticals Initiates Dosing of CRV431 in First In-Human Trial
finance.yahoo.com - June 25 at 8:53 AM
Pressing Questions For ContraVirs Management Ahead Of Mondays Investor ConferencePressing Questions For ContraVir's Management Ahead Of Monday's Investor Conference
seekingalpha.com - June 22 at 5:35 PM
Form 8-K ContraVir Pharmaceutical For: Jun 18Form 8-K ContraVir Pharmaceutical For: Jun 18
www.streetinsider.com - June 21 at 8:54 AM
ContraVir Pharma (CTRV) Regains Compliance with Nasdaq Listing RequirementsContraVir Pharma (CTRV) Regains Compliance with Nasdaq Listing Requirements
www.streetinsider.com - June 21 at 8:54 AM
Form 8-K ContraVir Pharmaceutical For: Jun 20Form 8-K ContraVir Pharmaceutical For: Jun 20
www.streetinsider.com - June 21 at 8:54 AM
ContraVir Pharmaceuticals Announces Data on Optimized Formulation of TXL™ContraVir Pharmaceuticals Announces Data on Optimized Formulation of TXL™
finance.yahoo.com - June 21 at 8:54 AM
ContraVir Pharmaceuticals Regains Compliance with Nasdaq Listing RequirementsContraVir Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements
finance.yahoo.com - June 20 at 5:52 PM
ContraVir Pharmaceuticals to Provide Corporate, Business and Clinical UpdatesContraVir Pharmaceuticals to Provide Corporate, Business and Clinical Updates
finance.yahoo.com - June 18 at 6:39 PM
This page was last updated on 6/17/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel